source
- TScan Therapeutics cuts 75% of staff to focus on preclinical solid tumor programsTScan Therapeutics said it will cut about three quarters of its workforce after pausing its hematological and autoimmune programs. The company will shift resources to its preclinical solid tumor p…
- Moderna and Merck's mRNA cancer vaccine extends survival in phase 3 melanoma trialMerck and Moderna reported that their personalized mRNA cancer vaccine improved patient outcomes in a late-stage study. The phase 3 INTerpath-001 trial enrolled 1,137 patients who had surgery to r…